Neovasc Inc announced that its Neovasc Reducer product for refractory angina was featured in a “live case” broadcast at the 10th Annual Congress of Update in Cardiology and Cardiovascular Surgery held in Antalya, Turkey. In the live case broadcast, Pierfrancesco Agostoni and Eric Duckers of the University Medical Center Utrecht in the Netherlands successfully implanted a Neovasc Reducer product in the coronary sinus of a 64-year old male patient suffering from refractory angina.
The Neovasc Reducer is a stent-like device that is CE marked for refractory angina, a painful and debilitating condition with no current treatment options. The Reducer is implanted using a straightforward, minimally invasive transvenous procedure.
Refractory angina affects millions of patients worldwide, who typically lead severely restricted lives as a result of their disabling symptoms, and its incidence is growing. The Reducer provides treatment for angina symptoms by altering blood flow in the heart muscle’s circulatory system, thereby increasing the perfusion of oxygenated blood to ischaemic areas of the heart muscle. Placement of the Reducer is performed using a minimally invasive transvenous procedure that is similar to implanting a coronary stent and takes approximately 20 minutes.
The results of the COSIRA study, a multicentre, randomised, sham controlled study conducted to evaluate the safety and effectiveness of the Reducer will be presented as a Featured Clinical Research Presentation at the American College of Cardiology 63rd Annual Scientific Session & Expo being held in Washington DC, March 29-31, 2014. Principal investigator Stefan Verheye will present the full results of the trial at a session being held on March 29. In November, 2013, Neovasc announced topline data from the COSIRA study indicating that the trial had met its primary efficacy endpoint.